Duncan A. Greenhalgh

Duncan A. Greenhalgh

Duncan A. Greenhalgh

Duncan Greenhalgh is a partner in Goodwin's Technology Companies & Life Sciences Group. He has over 17 years of experience advising life science companies, ranging in size from start-ups to public companies, and academic institutions on complex intellectual property matters and market exclusivity strategies. Dr. Greenhalgh also represents venture capital funds on intellectual property matters relating to their investments in life sciences companies, and investment banks on intellectual property matters relating to public and private financings.

Dr. Greenhalgh has been recognized by Chambers USA: America’s Leading Lawyers for Business (2009-2014), LMG Life Sciences (2012-2014) and Intellectual Asset Management’s Patent 1000 (2015-2016) as an industry leader for his intellectual property expertise in life sciences.

Professional Activities

Dr. Greenhalgh is a member of a number of professional organizations, including the American Intellectual Property Law Association, the American Bar Association, the Boston Bar Association and the Boston Patent Law Association.

Professional Experience

Prior to joining Goodwin in 2005, Dr. Greenhalgh was a senior associate at Testa, Hurwitz & Thibeault LLP in the Patent and Intellectual Property Practice Group.


Dr. Greenhalgh has been selected for inclusion in Chambers USA: America's Leading Lawyers for Business, 2009 - 2015, and LMG Life Sciences, 2012 - 2014.

Areas of Practice


Dr. Greenhalgh has extensive experience counseling biotechnology, pharmaceutical, diagnostics and medical device companies, research institutions and hospitals on intellectual property matters, with particular emphasis on the procurement and enforcement of patent rights.  He specializes in developing and managing domestic and foreign patent portfolios, including developing, implementing and expediting complex prosecution strategies in the United States and abroad, and has handled numerous post grant proceedings, including reissue, ex parte and inter partes reexamination, and interference proceedings at the United States Patent and Trademark Office, and foreign patent opposition proceedings. Dr. Greenhalgh has obtained patent protection for various FDA-approved therapeutics and diagnostics, and advises clients on Orange Book listing and life cycle management issues.

Dr. Greenhalgh conducts intellectual property due diligence investigations in connection with various transactions, including investments in public and privately held companies, public offerings, licensing transactions, strategic alliances, and mergers and acquisitions.

Representative Matters

Patent Portfolio Development and Counseling
  • Ongoing representation of various privately held and public companies including Altus Formulation, AVEO Pharmaceuticals, Catabasis Pharmaceuticals, Charles River Laboratories, CytoPherx, Endomedix, Ensemble Therapeutics, GliaCure, Immune Targeting Systems, Lysosomal Therapeutics, Inc., the Massachusetts Eye and Ear Infirmary, Melinta Therapeutics, Paladin Labs, ProQR Therapetics, and  VisEn Medical, in intellectual property matters
  • Full life cycle patent strategy on behalf of global pharmaceutical company with approved product, including expedited patent prosecution, patent term extension, and related Orange Book listings
  • ProQR Therapeutics in its patent matters and its recent $97.5 million public offering
  • AVEO Pharmaceuticals on patent matters relating to its product candidates, initial public offering and follow-on offerings, and strategic partnerships
  • Action Pharma, in the $110 million sale of rights to develop and commercialize the kidney drug compound AP214 to Abbott Laboratories
IP Due Diligence
  • Representation of the underwriters during the initial public offerings and follow-on offerings for Intrexon Corporation (in one of the largest ever biotech IPOs), Argos Therapeutics, BioAmber, Intercept Pharmaceuticals, ProQR Therapeutics, Tokai Pharmaceuticals, OvaScience, and Supernus Pharmaceuticals
  • Lightstone Ventures and others in connection with venture investment in Catabasis Pharmaceuticals
  • Atlas Venture and others in connection with venture investments in Harbour Antibodies and Lysosomal Therapeutics, Inc.
  • Bessemer Venture Partners and General Catalyst in connection with multiple rounds of venture investment in OvaScience
  • Other leading VC firms including Apposite Capital, Fidelity, and Xeraya Capital in connection with their investments



J.D., 1998
Suffolk University School of Law

(magna cum laude)

Ph.D., Biochemistry, 1989
University of Leeds
B.Sc., Biotechnology, 1985
University of Leeds

(with honors)



U.S. Patent and Trademark Office (USPTO)


U.S. Court of Appeals for the Federal Circuit
U.S. District Court for the District of Massachusetts
Get In Touch
Our clients rely on us for world-class advisory services, counsel on complex transactional work and high-stakes litigation. Specializing in matters involving the financial, life sciences, private equity, real estate, and technology industries, we use a collaborative, cross-disciplinary approach to resolve our clients’ most challenging issues. To find out more, please contact us.
Search Other Lawyers